These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 395139)

  • 1. The effect of BCNU combined with total body irradiation or cyclophosphamide on survival of dogs after autologous marrow grafts.
    Paterson AH; English D
    Int J Radiat Oncol Biol Phys; 1979 Sep; 5(9):1585-7. PubMed ID: 395139
    [No Abstract]   [Full Text] [Related]  

  • 2. Combination of high-dose cyclophosphamide, BCNU, and VP-16-213 followed by autologous marrow rescue in the treatment of relapsed leukemia.
    Zander AR; Vellekoop L; Spitzer G; Verma DS; Litam J; McCredie KB; Keating M; Hester JP; Dicke KA
    Cancer Treat Rep; 1981; 65(5-6):377-81. PubMed ID: 7016323
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prolongation of survival for high-grade malignant gliomas with adjuvant high-dose BCNU and autologous bone marrow transplantation.
    Johnson DB; Thompson JM; Corwin JA; Mosley KR; Smith MT; de los Reyes RA; Daly MB; Petty AM; Lamaster D; Pierson WP
    J Clin Oncol; 1987 May; 5(5):783-9. PubMed ID: 3553437
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Autologous bone-marrow transplantation: host effects of high-dose BCNU.
    Takvorian T; Parker LM; Hochberg FH; Canellos GP
    J Clin Oncol; 1983 Oct; 1(10):610-20. PubMed ID: 6366127
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-dose BCNU therapy with autologous bone marrow infusion: preliminary observations.
    Spitzer G; Dicke KA; Verma DS; Zander A; McCredie KB
    Cancer Treat Rep; 1979 Aug; 63(8):1257-64. PubMed ID: 383292
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-dose chemotherapy with BEAC regimen and autologous bone marrow transplantation for intermediate grade and immunoblastic lymphoma: durable complete remissions, but a high rate of regimen-related toxicity.
    van Besien K; Tabocoff J; Rodriguez M; Andersson B; Mehra R; Przepiorka D; Dimopoulos M; Giralt S; Suki S; Khouri I
    Bone Marrow Transplant; 1995 Apr; 15(4):549-55. PubMed ID: 7655380
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Total body irradiation and high-dose cyclophosphamide, BCNU and VP-16 (CBV) as a new preparatory regimen for allogeneic bone marrow transplantation in patients with advanced hematologic malignancies.
    Wu DP; Milpied N; Moreau P; Mechinaud-Lacroix F; Mahe B; Le Tortorec S; Rapp MJ; Bourdin S; Mahe JM; Harousseau JL
    Bone Marrow Transplant; 1994 Nov; 14(5):751-7. PubMed ID: 7889008
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intensive chemotherapy with cyclophosphamide, carmustine, and etoposide followed by autologous bone marrow transplantation for relapsed Hodgkin's disease.
    Reece DE; Barnett MJ; Connors JM; Fairey RN; Fay JW; Greer JP; Herzig GP; Herzig RH; Klingemann HG; LeMaistre CF
    J Clin Oncol; 1991 Oct; 9(10):1871-9. PubMed ID: 1919637
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-dose combination alkylating agent therapy with autologous bone marrow rescue for refractory solid tumors.
    Slease RB; Benear JB; Selby GB; Reitz CL; Hughes WL; Watkins CL; Epstein RB
    J Clin Oncol; 1988 Aug; 6(8):1314-20. PubMed ID: 3045266
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Haemolytic uraemic syndrome and renal dysfunction following BEAC (BCNU, etoposide, ara-C, cyclophosphamide) +/- TBI and autologous BMT for malignant lymphomas.
    Carlson K; Smedmyr B; Hagberg H; Oberg G; Simonsson B
    Bone Marrow Transplant; 1993 Mar; 11(3):205-8. PubMed ID: 8467284
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early pulmonary toxicity after administration of high-dose BCNU.
    Litam JP; Dail DH; Spitzer G; Vellekoop L; Verma DS; Zander AR; Dicke KA
    Cancer Treat Rep; 1981; 65(1-2):39-44. PubMed ID: 6261949
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bone marrow transplantation through standard central venous catheters.
    Gallardo D; Alonso E; Riu C; Ponce C; Salar A; Ferrà C; Berlanga JJ; Grañena A
    Transplant Proc; 1995 Aug; 27(4):2354. PubMed ID: 7652839
    [No Abstract]   [Full Text] [Related]  

  • 13. Prognostic factors for treatment outcome in autotransplantation of intermediate-grade and high-grade non-Hodgkin's lymphoma with cyclophosphamide, carmustine, and etoposide.
    Wheeler C; Strawderman M; Ayash L; Churchill WH; Bierer BE; Elias A; Gilliland DG; Antman K; Guinan EC; Eder JP
    J Clin Oncol; 1993 Jun; 11(6):1085-91. PubMed ID: 8099120
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intensive 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU), NSC #4366650 and cryopreserved autologous marrow transplantation for refractory cancer. A phase I-II study.
    Phillips GL; Fay JW; Herzig GP; Herzig RH; Weiner RS; Wolff SN; Lazarus HM; Karanes C; Ross WE; Kramer BS
    Cancer; 1983 Nov; 52(10):1792-802. PubMed ID: 6354414
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-dose cyclophosphamide, carmustine, and etoposide and autologous bone marrow transplantation for relapsed Hodgkin's disease.
    Jagannath S; Dicke KA; Armitage JO; Cabanillas FF; Horwitz LJ; Vellekoop L; Zander AR; Spitzer G
    Ann Intern Med; 1986 Feb; 104(2):163-8. PubMed ID: 3511811
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Repeated high-dose chemotherapy followed by purged autologous bone marrow transplantation as consolidation therapy in metastatic neuroblastoma.
    Hartmann O; Benhamou E; Beaujean F; Kalifa C; Lejars O; Patte C; Behard C; Flamant F; Thyss A; Deville A
    J Clin Oncol; 1987 Aug; 5(8):1205-11. PubMed ID: 3305792
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nursing management of the patient receiving high-dose BCNU with autologous bone marrow harvest.
    Gamel-Bentzel C
    J Neurosurg Nurs; 1982 Apr; 14(2):98-102. PubMed ID: 6288899
    [No Abstract]   [Full Text] [Related]  

  • 18. Regimen-related toxicity and non-relapse mortality with high-dose cyclophosphamide, carmustine (BCNU) and etoposide (VP16-213) (CBV) and CBV plus cisplatin (CBVP) followed by autologous stem cell transplantation in patients with Hodgkin's disease.
    Reece DE; Nevill TJ; Sayegh A; Spinelli JJ; Brockington DA; Barnett MJ; Klingemann HG; Connors JM; Nantel SH; Shepherd JD; Sutherland HJ; Voss NJ; Fairey RN; O'Reilly SE; Phillips GL
    Bone Marrow Transplant; 1999 Jun; 23(11):1131-8. PubMed ID: 10382952
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic factors for response and survival after high-dose cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation for relapsed Hodgkin's disease.
    Jagannath S; Armitage JO; Dicke KA; Tucker SL; Velasquez WS; Smith K; Vaughan WP; Kessinger A; Horwitz LJ; Hagemeister FB
    J Clin Oncol; 1989 Feb; 7(2):179-85. PubMed ID: 2644397
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized trial of high-dose chemotherapy with autologous bone marrow support as adjuvant therapy for high-risk, multi-node-positive malignant melanoma.
    Meisenberg BR; Ross M; Vredenburgh JJ; Jones R; Shpall EJ; Seigler HF; Coniglio DM; Wu K; Peters WP
    J Natl Cancer Inst; 1993 Jul; 85(13):1080-5. PubMed ID: 8515495
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.